{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:55Z","timestamp":1790217415189,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["106-2314-B-182A-040-MY3"],"award-info":[{"award-number":["106-2314-B-182A-040-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3F0191-3"],"award-info":[{"award-number":["CMRPG3F0191-3"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ophtha.2019.03.048","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T02:14:05Z","timestamp":1554430445000},"page":"1567-1577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-3443","authenticated-orcid":false,"given":"Yuan-Yao","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Fu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Pang","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Shiou","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Chieh","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2019.03.048_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/08820538.2015.1114847","article-title":"Role of VEGF inhibition in the treatment of retinopathy of prematurity","volume":"31","author":"Eldweik","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/pch\/21.2.101","article-title":"Retinopathy of prematurity: an update on screening and management","volume":"21","author":"Jefferies","year":"2016","journal-title":"Paediatrics & Child Health"},{"key":"10.1016\/j.ophtha.2019.03.048_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5409\/wjcp.v5.i1.35","article-title":"Retinopathy of prematurity: past, present and future","volume":"5","author":"Shah","year":"2016","journal-title":"World J Clin Pediatrics"},{"key":"10.1016\/j.ophtha.2019.03.048_bib4","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2019.03.048_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.03.048_bib8","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10495-006-8762-3","article-title":"General anesthesia activates BDNF-dependent neuroapoptosis in the developing rat brain","volume":"11","author":"Lu","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.ophtha.2019.03.048_bib9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/jpsu.2001.23954","article-title":"Educational attainments in early adolescence of infants who required major neonatal surgery","volume":"36","author":"Ludman","year":"2001","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.ophtha.2019.03.048_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1750-3639.2007.00116.x","article-title":"Clinical anesthesia causes permanent damage to the fetal guinea pig brain","volume":"18","author":"Rizzi","year":"2008","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2006.11.039","article-title":"Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms","volume":"150","author":"Kabra","year":"2007","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ophtha.2019.03.048_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1440-1754.2006.00969.x","article-title":"Neurodevelopmental outcomes and surgery in neonates","volume":"42","author":"Walker","year":"2006","journal-title":"J\u00a0Paediatr Child Health"},{"key":"10.1016\/j.ophtha.2019.03.048_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMp1700196","article-title":"Anesthesia and developing brains\u2014implications of the FDA warning","volume":"376","author":"Andropoulos","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2019.03.048_bib14","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.ophtha.2017.05.007","article-title":"Re: Good: bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843\u20131844)","volume":"124","author":"Blair","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.048_bib15","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.03.048_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.03.048_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1523\/JNEUROSCI.4445-12.2013","article-title":"Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth","volume":"33","author":"Malik","year":"2013","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ophtha.2019.03.048_bib20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/dev.114.2.521","article-title":"Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation","volume":"114","author":"Breier","year":"1992","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.ophtha.2019.03.048_bib21","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.ophtha.2019.03.048_bib22","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2019.03.048_bib23","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib24","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2019.03.048_bib25","first-page":"61","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2019.03.048_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.048_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/bjo.2003.041186","article-title":"Refraction and keratometry in premature infants","volume":"88","author":"Repka","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1475-1313.1992.tb00300.x","article-title":"New acuity test for toddlers","volume":"12","author":"Woodhouse","year":"1992","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ophtha.2019.03.048_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0042-6989(94)90168-6","article-title":"The Cardiff acuity test used for measuring visual acuity development in toddlers","volume":"34","author":"Adoh","year":"1994","journal-title":"Vision Res"},{"key":"10.1016\/j.ophtha.2019.03.048_bib30","series-title":"Bayley Scales of Infant and Toddler Development","author":"Bayley","year":"2006"},{"key":"10.1016\/j.ophtha.2019.03.048_bib31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A\u00a0systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib32","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"issue":"4","key":"10.1016\/j.ophtha.2019.03.048_bib33","doi-asserted-by":"crossref","first-page":"e20160057","DOI":"10.1542\/peds.2016-0057","article-title":"Concerns for development after bevacizumab treatment of ROP","volume":"137","author":"Quinn","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2019.03.048_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.048_bib35","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib36","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.048_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.03.048_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib41","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1523\/JNEUROSCI.21-10-03332.2001","article-title":"Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor","volume":"21","author":"Bagnard","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ophtha.2019.03.048_bib42","doi-asserted-by":"crossref","first-page":"11946","DOI":"10.1073\/pnas.182296499","article-title":"Vascular endothelial growth factor (VEGF) stimulates neurogenesis in\u00a0vitro and in\u00a0vivo","volume":"99","author":"Jin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2019.03.048_bib43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1083\/jcb.200308040","article-title":"VEGF is a chemoattractant for FGF-2-stimulated neural progenitors","volume":"163","author":"Zhang","year":"2003","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.03.048_bib45","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0161-6420(98)97036-1","article-title":"Prevalence of myopia between 3 months and 5 1\/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"105","author":"Quinn","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.048_bib46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/bjo.84.2.138","article-title":"Long term refractive outcome in eyes of preterm infants with and without retinopathy of prematurity: comparison of keratometric value, axial length, anterior chamber depth, and lens thickness","volume":"84","author":"Choi","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.2004.045815","article-title":"Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months","volume":"89","author":"Sahni","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib48","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1167\/iovs.06-0114","article-title":"Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity","volume":"49","author":"Cook","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.03.048_bib49","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1167\/iovs.10-5234","article-title":"Long-term evaluation of refractive status and optical components in eyes of children born prematurely","volume":"51","author":"Chen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2019.03.048_bib50","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archophthalmol.2012.1","article-title":"Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"Harder","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib52","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2019.03.048_bib53","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/OPTH.S110717","article-title":"Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity","volume":"10","author":"Lin","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib54","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":"Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity","volume":"31","author":"Axer-Siegel","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2019.03.048_bib55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archopht.1996.01100130413008","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1\/2 years after randomization","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.048_bib56","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2019.03.048_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IAE.0000000000000270","article-title":"Natural history of retinopathy of prematurity: two-year outcomes of a prospective study","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018317998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018317998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:52:50Z","timestamp":1777492370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018317998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0161642018317998"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.048","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}